Merck Becomes Member of the Worldwide Innovative Network in Personalized Cancer Medicine - WIN Consortium (Paris)
Worldwide Innovative Network in Personalized Cancer Medicine - WIN Consortium proudly announces today that Merck, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, be
2017년 6월 16일 13:55
SERMO - the largest global social network for physicians that is revolutionizing medical crowdsourcing - today furthered its goal of uniting doctors worldwide by expanding to more than 150 countries.
2017년 6월 15일 12:10
Chiltern Acquires Japanese Clinical Research Organization Integrated Development Associates Co. Ltd.
Chiltern, a leading global contract research organization, has acquired Integrated Development Associates Co. Ltd. (IDA), a CRO specializing in integrating Japan and Asia into global drug development.
2017년 6월 1일 13:50
Boston Healthcare Associates and Data Information Intelligence Announce Global Life Sciences Data Commercialization Partnership
Boston Healthcare Associates, Inc. (Boston Healthcare), a global life sciences consultancy, and Data Information Intelligence GmbH (dii) today announced a new partnership to develop and commercialize
2017년 6월 1일 13:35
PSMF Invites International Patient Safety Community to Attend its 5th Annual Midyear Planning Meeting on July 13, 2017
The Patient Safety Movement Foundation (PSMF) invites patient safety experts, medical care providers, hospital administrators, patient advocates and policy makers from around the world to discuss chal
2017년 4월 12일 17:00
The Patient Safety Movement Foundation (PSMF) announces the 3rd Annual Patient Safety Innovation Awards will open on April 3, 2017 at 12:00 PM PDT. The competition encourages entrepreneurs and patient
2017년 4월 4일 13:40
REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) as monotherapy for
2017년 2월 27일 09:45